Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif
Background<p>Advanced triple-negative breast cancer (TNBC) presents significant therapeutic challenges, particularly in Asian populations, which exhibit distinct biological and genetic characteristics. Immunotherapy combined with chemotherapy has emerged as a promising approach; however, its e...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1852022401363083264 |
|---|---|
| author | Hua Ruan (195072) |
| author2 | Yubin Zou (19832671) Lifeng Huang (5211407) Wenjuan Zha (2720134) Qingqing Ouyang (10175801) Ling Yang (34478) |
| author2_role | author author author author author |
| author_facet | Hua Ruan (195072) Yubin Zou (19832671) Lifeng Huang (5211407) Wenjuan Zha (2720134) Qingqing Ouyang (10175801) Ling Yang (34478) |
| author_role | author |
| dc.creator.none.fl_str_mv | Hua Ruan (195072) Yubin Zou (19832671) Lifeng Huang (5211407) Wenjuan Zha (2720134) Qingqing Ouyang (10175801) Ling Yang (34478) |
| dc.date.none.fl_str_mv | 2025-02-28T06:52:30Z |
| dc.identifier.none.fl_str_mv | 10.3389/fonc.2025.1540538.s009 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Image_2_PD-1_PD-L1_inhibitors_plus_chemotherapy_versus_chemotherapy_alone_for_Asian_patients_with_advanced_triple-negative_breast_cancer_a_phase_III_RCTs_based_meta-analysis_tif/28511417 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Oncology and Carcinogenesis not elsewhere classified PD-1/PD-L1 inhibitors chemotherapy triple-negative breast cancer randomized controlled trials meta-analysis |
| dc.title.none.fl_str_mv | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | Background<p>Advanced triple-negative breast cancer (TNBC) presents significant therapeutic challenges, particularly in Asian populations, which exhibit distinct biological and genetic characteristics. Immunotherapy combined with chemotherapy has emerged as a promising approach; however, its efficacy compared to chemotherapy alone remains under investigation. This meta-analysis aims to evaluate the clinical outcomes of PD-1/PD-L1 inhibitors combined with chemotherapy (PIC) versus chemotherapy alone in the treatment of advanced TNBC in Asian patients.</p>Methods<p>A systematic literature search was performed across six databases for phase 3 randomized controlled trials (RCTs). Only studies comparing the outcomes of PIC versus chemotherapy alone in patients with advanced TNBC, including subgroup analyses of Asian populations, were included. Data were pooled to assess overall survival (OS), progression-free survival (PFS), responses, and safety profiles.</p>Results<p>A total of 1041 patients from five phase 3 RCTs were included in the final analysis. Compared to chemotherapy alone, PIC therapy significantly improved PFS (hazard ratio [HR]: 0.74 [0.62, 0.88], P = 0.0008). No significant difference was observed in OS (HR: 0.78 [0.55, 1.12], P = 0.18), although a slight trend favoring PIC therapy was noted. Among PD-L1-positive patients, both OS (HR: 0.62 [0.44, 0.86], P = 0.005) and PFS (HR: 0.66 [0.50, 0.86], P = 0.003) were significantly improved in the PIC group. The PIC group also exhibited a substantially higher OS rate at 12–36 months and a higher PFS rate at 6–30 months. However, the incidence of immune-related AEs (irAEs) (risk ratio [RR]: 1.69 [1.33, 2.15], P < 0.0001) and grade 3–5 irAEs (RR: 3.11 [1.59, 6.10], P = 0.001) was significantly higher in the PIC group. The most common irAEs in the PIC group were hypothyroidism (14.40%), dermatitis (10.00%), and infusion reactions (8.85%). Both treatment groups exhibited similar response rates and treatment-related AEs (TRAEs).</p>Conclusions<p>In Asian patients with advanced TNBC, PIC significantly improved survival compared to chemotherapy alone. Although the combination therapy was associated with a higher incidence of irAEs, its clinical benefits support its use as a viable treatment option for this population.</p>Systematic review registration<p>https://www.crd.york.ac.uk/prospero/, identifier CRD42024622428.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_82f16db56d4f2aae5f6a34dd67f371fc |
| identifier_str_mv | 10.3389/fonc.2025.1540538.s009 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/28511417 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tifHua Ruan (195072)Yubin Zou (19832671)Lifeng Huang (5211407)Wenjuan Zha (2720134)Qingqing Ouyang (10175801)Ling Yang (34478)Oncology and Carcinogenesis not elsewhere classifiedPD-1/PD-L1 inhibitorschemotherapytriple-negative breast cancerrandomized controlled trialsmeta-analysisBackground<p>Advanced triple-negative breast cancer (TNBC) presents significant therapeutic challenges, particularly in Asian populations, which exhibit distinct biological and genetic characteristics. Immunotherapy combined with chemotherapy has emerged as a promising approach; however, its efficacy compared to chemotherapy alone remains under investigation. This meta-analysis aims to evaluate the clinical outcomes of PD-1/PD-L1 inhibitors combined with chemotherapy (PIC) versus chemotherapy alone in the treatment of advanced TNBC in Asian patients.</p>Methods<p>A systematic literature search was performed across six databases for phase 3 randomized controlled trials (RCTs). Only studies comparing the outcomes of PIC versus chemotherapy alone in patients with advanced TNBC, including subgroup analyses of Asian populations, were included. Data were pooled to assess overall survival (OS), progression-free survival (PFS), responses, and safety profiles.</p>Results<p>A total of 1041 patients from five phase 3 RCTs were included in the final analysis. Compared to chemotherapy alone, PIC therapy significantly improved PFS (hazard ratio [HR]: 0.74 [0.62, 0.88], P = 0.0008). No significant difference was observed in OS (HR: 0.78 [0.55, 1.12], P = 0.18), although a slight trend favoring PIC therapy was noted. Among PD-L1-positive patients, both OS (HR: 0.62 [0.44, 0.86], P = 0.005) and PFS (HR: 0.66 [0.50, 0.86], P = 0.003) were significantly improved in the PIC group. The PIC group also exhibited a substantially higher OS rate at 12–36 months and a higher PFS rate at 6–30 months. However, the incidence of immune-related AEs (irAEs) (risk ratio [RR]: 1.69 [1.33, 2.15], P < 0.0001) and grade 3–5 irAEs (RR: 3.11 [1.59, 6.10], P = 0.001) was significantly higher in the PIC group. The most common irAEs in the PIC group were hypothyroidism (14.40%), dermatitis (10.00%), and infusion reactions (8.85%). Both treatment groups exhibited similar response rates and treatment-related AEs (TRAEs).</p>Conclusions<p>In Asian patients with advanced TNBC, PIC significantly improved survival compared to chemotherapy alone. Although the combination therapy was associated with a higher incidence of irAEs, its clinical benefits support its use as a viable treatment option for this population.</p>Systematic review registration<p>https://www.crd.york.ac.uk/prospero/, identifier CRD42024622428.</p>2025-02-28T06:52:30ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.3389/fonc.2025.1540538.s009https://figshare.com/articles/figure/Image_2_PD-1_PD-L1_inhibitors_plus_chemotherapy_versus_chemotherapy_alone_for_Asian_patients_with_advanced_triple-negative_breast_cancer_a_phase_III_RCTs_based_meta-analysis_tif/28511417CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/285114172025-02-28T06:52:30Z |
| spellingShingle | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif Hua Ruan (195072) Oncology and Carcinogenesis not elsewhere classified PD-1/PD-L1 inhibitors chemotherapy triple-negative breast cancer randomized controlled trials meta-analysis |
| status_str | publishedVersion |
| title | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| title_full | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| title_fullStr | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| title_full_unstemmed | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| title_short | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| title_sort | Image 2_PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysis.tif |
| topic | Oncology and Carcinogenesis not elsewhere classified PD-1/PD-L1 inhibitors chemotherapy triple-negative breast cancer randomized controlled trials meta-analysis |